Washington hearing exposes sharp split over 340B expansion and reporting in SSB 5981
The House Appropriations Committee heard hours of technical briefings and sharply divided testimony on SSB 5981, which would expand reporting and fee authority tied to the federal 340B drug discount program. Safety‑net providers urged transparency to protect vulnerable patients; manufacturers and employers warned of lost rebates, higher costs and federal preemption risk.
The full story
Ethan Moreno and committee staff opened the hearing by briefing members on SSB 5981, which would require hospitals, federally qualified health centers and manufacturers to report acquisition costs, claims counts and other data about 340B‑eligible drugs to the Health Care Authority (HCA) and would allow HCA to set a tiered annual filing fee and civil penalties for noncompliance.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in